Outcome № of participants (studies) | Relative effect (95% CI) | Anticipated absolute effects (95% CI) | Certainty | ||
---|---|---|---|---|---|
Difference | |||||
HIV infection № of participants: 149 (1 RCT) | RR 0.07 (0.00 to 1.38) | 6.0% | 0.4% (0 to 8.3) | 5.6% fewer (6 fewer to 2.3 more) | ⨁⨁◯◯ LOW a |
Any STI № of participants: 2232 (3 RCTs) | RR 0.74 (0.62 to 0.89) | 24.9% | 18.4% (15.5 to 22.2) | 6.5% fewer (9.5 fewer to 2.7 fewer) | ⨁⨁⨁◯ MODERATE b |
Gonorrhoea № of participants: 790 (2 RCTs) | RR 0.59 (0.41 to 0.86) | 15.2% | 9.0% (6.2 to 13.1) | 6.2% fewer (9 fewer to 2.1 fewer) | ⨁⨁⨁⨁ HIGH |
Chlamydia № of participants: 790 (2 RCTs) | RR 0.67 (0.47 to 0.94) | 16.0% | 10.7% (7.5 to 15) | 5.3% fewer (8.5 fewer to 1 fewer) | ⨁⨁⨁⨁ HIGH |
Trichomonas № of participants: 790 (2 RCTs) | RR 1.01 (0.63 to 1.60) | 8.0% | 8.1% (5 to 12.8) | 0.1% more (3 fewer to 4.8 more) | ⨁⨁⨁◯ MODERATE a |
Genital ulcer disease № of participants: 457 (1 RCT) | RR 4.72 (0.23 to 97.87) | 0.0% | 0.0% (0 to 0) | 0.0% fewer (0 fewer to 0 fewer) | ⨁⨁⨁◯ MODERATE a |